ACCESS BIO, INC. Access Bio, Inc. Share Price
Equities
A950130
KR8840090003
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,410 KRW | +2.40% |
|
-0.62% | -28.54% |
| 2023 | Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc. | CI |
| 2023 | Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022. | CI |
| Sales 2022 | 1,034B 747M 62.44B | Sales 2023 | 349B 252M 21.06B | Capitalization | 303B 219M 18.29B |
|---|---|---|---|---|---|
| Net income 2022 | 347B 251M 20.94B | Net income 2023 | -3.17B -2.29M -192M | EV / Sales 2022 | -0.01 x |
| Net cash position 2022 | 423B 306M 25.56B | Net cash position 2023 | 274B 198M 16.54B | EV / Sales 2023 | 0.08 x |
| P/E ratio 2022 |
1.32
x | P/E ratio 2023 |
-95.5
x | Employees | 101 |
| Yield 2022 |
6.75% | Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.40% | ||
| 1 week | -0.62% | ||
| Current month | -14.08% | ||
| 1 month | -14.08% | ||
| 3 months | -23.51% | ||
| 6 months | -23.69% | ||
| Current year | -28.54% |
1 week
6 250.00
6 490.00
1 month
6 250.007 580.00
Current year
6 250.009 240.00
1 year
6 250.0014 340.00
3 years
6 250.0039 400.00
5 years
1 580.0062 900.00
10 years
1 580.0062 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Ho Choi
CEO | Chief Executive Officer | 60 | 01/02/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Ho Choi
CEO | Chief Executive Officer | 60 | 01/02/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 6,410 | +2.40% | 52,589 |
| 26/24/26 | 6,260 | -1.88% | 70,369 |
| 25/24/25 | 6,380 | -0.78% | 43,467 |
| 24/24/24 | 6,430 | 0.00% | 44,474 |
| 23/24/23 | 6,430 | -0.31% | 52,191 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Access Bio, Inc. is engaged in research, development and manufacturing of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Its product list includes covid-19 detection kits, rapid diagnostic tests, analyzers and molecular diagnostics. Its covid-19 detection kits include CareStart COVID-19 Antigen Home Test, CareStart COVID-19 Antigen, CareStart COVID-19 MDx RT-PCR, CareStart COVID-19 lgM/lgG and CareStart EZ COVID-19 lgM/lgG. Its rapid diagnostic tests include CareStart EZ HIV, CareStart Flu A&B Plus+, CareStart G6PD RDT, CareStart Malaria RDT, CareStart Dengue RDT, care US HIV 1/2 and care US Syphilis. The analyzers include care SURE Analyzer 100, care SURE A1c Cartridge, care SURE ACR Cartridge, care SURE CRP Cartridge, care START S1 Analyzer and care START G6PD Biosensor. The molecular diagnostics include care GENE HPV Screening kit-H, care GENE Zika Virus RT-PCR kit, care GENE STD detection kit, care GENE Dengue Virus genotyping kit and others.
Calendar
30/04/2024
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -28.54% | 158M | |
| +0.80% | 12.95B | |
| -7.57% | 7.84B | |
| +2.79% | 5.5B | |
| +0.93% | 4.61B | |
| +8.48% | 4.61B | |
| +9.21% | 2.66B | |
| -13.46% | 2.08B | |
| -11.63% | 1.72B | |
| +3.45% | 1.79B |
- Stock Market
- Equities
- A950130 Stock
